02526nam 2200589 a 450 991096921660332120200520144314.097816080529741608052974(CKB)2670000000148694(EBL)864207(OCoLC)779141401(SSID)ssj0000942934(PQKBManifestationID)11492225(PQKBTitleCode)TC0000942934(PQKBWorkID)10976890(PQKB)11670260(OCoLC)785783102(MiAaPQ)EBC864207(DE-B1597)731336(DE-B1597)9781608052974(EXLCZ)99267000000014869420120315d2012 uy 0engur|n|---|||||txtccrMultiple myeloma a new era of treatment strategies /editors, Klaus Podar, Kenneth C. Anderson1st ed.[U.S.A.] Bentham Science Publishers[2012]1 online resource (217 p.)Description based upon print version of record.9781608056095 1608056090 Includes bibliographical references and index.section 1. Multiple myeloma -- section 2. Treatment guidelines -- section 3. The bone marrow microenvironment and the pathogenesis of multiple myeloma -- section 4. New treatment strategies.Multiple Myeloma (MM), the second most common blood cancer in adults, is a clonal plasma cell malignancy within the bone marrow characterized by osteolytic bone lesions, renal disease, and immunodeficiency. It is now well established that MM cell- induced disruption of the bone marrow homeostasis between the highly organized cellular and extracellular compartments supports MM cell proliferation, survival, migration, and drug resistance via activation of various signaling pathways. Based on this knowledge, the prototypic drugs thalidomide, bortezomib, and lenalidomide, which target both MM cellMultiple myelomaTreatmentMultiple myelomaTreatment.616.99/418616.99418Podar Klaus, authttp://id.loc.gov/vocabulary/relators/aut1800395Podar Klaus1800395Anderson Kenneth C876632MiAaPQMiAaPQMiAaPQBOOK9910969216603321Multiple myeloma4345157UNINA